Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

Various PD-1 and PD-L1 checkpoint inhibitors have been approved by U.S. regulators including blockbuster drugs Keytruda, Imfinzi, and Opdivo to treat different types of cancer. But that hasn’t stopped ...